作者: Shinobu Mochizuki , Akira Miyake , Kiyoshi Yahiro , Kazuhiro Nakatou , Masanori Miura
DOI:
关键词: Potassium channel 、 Antidementia drug 、 Chemistry 、 In vivo 、 Active ingredient 、 1,3,5-Triazine 、 Derivative (chemistry) 、 Pharmacology
摘要: An antidementia drug containing a BEC1 potassium channel inhibitor as the active ingredient. It is proved that has an effect of ameliorating learning disability and useful preventive or remedy for diseases in which seemingly participates, preferably dementia. More specifically, it confirmed exhibits vivo test. also found out compound having 2,4,6-trimaino-1,3,5-triazine inhibiting channel.